ArticleBMC cancer2018

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

Kyriakos P Papadopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.